维普期刊资源整合服务平台（V6.5）

71篇 您的检索式：作者名="MITA AC"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Phase Ⅰ and pharmcokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function 显示文摘	Mita AC Sweeney C J Baker SD	2006	J Clin Oncol2006，24，18：	1
2	Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，：	1
3	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
4	Survivin : key reg- ulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
5	Survivin : key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	CIin Cancer Res2008，14，16：	1
6	Heat shock proteins: A potentional anticancer target 显示文摘	Sankhala KK Mira MM Mita AC	2011	Curr Drug Targets2011，12，：	1
7	Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
8	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
9	Phase Ⅰ trail of the novel mammalian target of rapamycin inhibitor deforolimus ( AP23573 ; MK-8669 ) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies显示文摘	Mita AC Chu QS	2005	Clin Oncol2005，26，：	1
10	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin cancer Res2008，14，16：	1
11	Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function显示文摘	MITA AC SWEENEY CJ BAKER SD et ol	2006	J Clin Oncol2006，24，4：	1
12	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
13	Survivin: key reg- ulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawroeki ST etal	2008	Clin Cancer Res2008，14，16：	1
14	Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
15	Survivin:key regulator ofmitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
16	Phase Ⅰ and pharmacokinetic study of XRP6258 (RPR 116258A),a novel taxane,administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors显示文摘	Mita AC Denis LJ Rowinsky EK	2009	Clin Cancer Res2009，15，2：	1
17	Survivin: key reg-ulator of mitosis and apoptosis and novel target for cancertherapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，：	1
18	Phase I and pharmacokinetic study of XRP6258 (RPR 116258A),a novel taxane,administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors显示文摘	MITA AC DENIS LJ ROWINSKY EK	2009	Clin Cancer Res2009，15，2：	1
19	Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Altieri DC Marchisio PC Mita AC	2008	Clin Cancer Res2008，1514，16：	1
20	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mira MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示